Project Grant R21CA280319
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$192K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
The University of Texas Southwestern Medical Center (UT Southwestern) received a $642,429 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to study acquired cross-resistance in small cell lung cancer (SCLC). The funding will support research using a panel of 72 patient-derived xenograft models to investigate how genetic alterations, specifically extrachromosomal amplification of MYC family genes, drive resistance to both standard chemotherapies...
The University of Chicago was awarded a $230,010 Project Grant by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop innovative methods and tools to investigate the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The research strategy will integrate human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing...
This Federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Duke University is for $122,834 and will run from December 1, 2024 to May 31, 2026. The grant supports research to investigate how inhibition of ABL kinases affects metabolic function and dysregulation in small cell lung cancer (SCLC), and how combining ABL kinase inhibition with inhibition of MCT transporters may induce ferroptotic cell death in SCLC. The research aims to determine...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $530,786 to The Leland Stanford Junior University to conduct research focused on modulating cysteine metabolism to induce cell death in small cell lung cancer (SCLC). The key objectives are to:
Determine how distinct neuroendocrine SCLC cell states dictate the choice to die by apoptosis versus ferroptosis, focusing on the role of the GCN2/ATF4 amino acid sensing pathway and...
This Project Grant award of $3,787,956 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research by New York University (NYU) School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The key objectives are to:
Understand how the gene SLFN11 informs chemosensitivity in SCLC subtypes.
Study how replication stress response pathways and replication fork modulators regulate...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Icahn School of Medicine at Mount Sinai to elucidate the mechanistic roles of lineage factors in distinct lineage subtypes of small cell lung cancer (SCLC). The project aims to: 1) determine how cell-of-origin and the transcription factor NKX2-1 impact the evolution and maintenance of epigenomic SCLC states, 2) determine the mechanisms for pulmonary to neuronal...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $216,972 to Temple University to conduct research aimed at understanding and targeting vulnerabilities in small cell lung cancer (SCLC). The key research objectives are to:
Determine the mechanisms driving increased replication stress in SCLC, particularly the role of the nuclear structural protein LMNA and R-loops, and explore targeting these...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $548,915 to the Fred Hutchinson Cancer Center in Seattle, WA to investigate a novel tumor suppressive pathway in small cell lung cancer (SCLC). The research aims to leverage cellular models, genetically engineered mouse models, and human tumor datasets to elucidate the biological roles of the stress-activated protein kinase (SAPK) axis in...
This $1,408,844.00 Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), will fund research to characterize the diagnostic and therapeutic potential of Delta-Like Ligand 3 (DLL3)-targeting agents for high-grade neuroendocrine carcinomas of the lung (small cell lung cancer) and prostate.
The research aims to evaluate a DLL3-targeted radiolabeled monoclonal antibody for PET imaging (89Zr-DFO-SC16.56 AB) to non-invasively...
The University of Texas Southwestern Medical Center received a $164,000 Project Grant award from the Defense Health Agency on December 15, 2022 to fund research titled "Overcoming Jumonji KDM4A Oncogenic Function in SCLC" through December 14, 2023.
The grant supports the Military Medical Research and Development program of the Defense Health Agency, which aims to transform military and public health through innovative medical research solutions. Specifically, the grant will fund the...